Ocugen shares rise as H.C. Wainwright lifts price target to $8
H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...
来自MSN15 小时
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone ...
Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
Knowridge22 小时
Older women may face higher risk from gene therapy for eye diseases
Unlike older male eye cells, which showed a consistent immune response pattern, older female eye cells appeared to experience ...